References
- Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168–71
- Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996; 70: 7894–9
- Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 d vs 6–8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20: 595–9
- Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T-cells. Nat Med 2003; 9: 727–8
- Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, et al. Long-term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487–94
- Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38: 37–42
- Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 2004; 78: 4234–47
- Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188–91
- Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76: 1753–61
- Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188: 1433–43
- Mohey, R, Jorgensen, LB, Moller, BK, Black, FT, Kjems, J, Obel, N. Detection and quantification of proviral HIV-1 184M/V in circulating CD4+ T-cells of patients on HAART with a viraemia less than 1000 copies/ml. J Clin Virol 2005; In press.
- Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189: 1452–65
- Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18: 1683–9
- Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512–7
- Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T-cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1: 1284–90
- Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183–8
- Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T- cells. Nat Med 2003; 9: 727–8
- Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6: 82–5
- Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18: 1147–58